Table of Contents Author Guidelines Submit a Manuscript
Letter to the Editor
Case Reports in Dentistry
Volume 2016 (2016), Article ID 8648949, 6 pages
http://dx.doi.org/10.1155/2016/8648949
Case Report

World’s First Clinical Case of Gene-Activated Bone Substitute Application

1Department of Maxillofacial and Plastic Surgery, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia
2Human Stem Cells Institute, Moscow, Russia
3Department of Maxillofacial Surgery, A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia
4I.P. Pavlov Ryazan State Medical University, Ryazan, Russia
5Central Clinical Hospital with Outpatient Health Center of the Business Administration for the President of the Russian Federation, Moscow, Russia

Received 16 July 2016; Accepted 12 October 2016

Academic Editor: Luis M. J. Gutierrez

Copyright © 2016 I. Y. Bozo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Treatment of patients with large bone defects is a complex clinical problem. We have initiated the first clinical study of a gene-activated bone substitute composed of the collagen-hydroxyapatite scaffold and plasmid DNA encoding vascular endothelial growth factor. The first patient with two nonunions of previously reconstructed mandible was enrolled into the study. Scar tissues were excised; bone defects (5–14 mm) between the mandibular fragments and nonvascularized rib-bone autograft were filled in with the gene-activated bone substitute. No adverse events were observed during 12 months of follow-up. In 3 months, the average density of newly formed tissues within the implantation zone was 402.21 ± 84.40 and 447.68 ± 106.75 HU in the frontal and distal regions, respectively, which correlated with the density of spongy bone. Complete distal bone defect repair with vestibular and lingual cortical plates formation was observed in 6 and 12 months after surgery; thereby the posterior nonunion was successfully eliminated. However, there was partial resorption of the proximal edge of the autograft entailed to relapse of the anterior nonunion. Thus, the first clinical data on the safety and efficacy of the gene-activated bone substitute were obtained. Given a high complexity of the clinical situation the treatment, results might be considered as promising. NCT02293031.